anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIMS: Although guidelines for the management of atrial fibrillation (AF) are regularly published, many controversial issues remain, limiting their implementation. We aim to describe current clinical practice among European Heart Rhythm Association (EHRA) community according to last guidelines.
METHODS AND RESULTS: A 30 multiple-choice questionnaire covering the most controversial topics related to AF management was distributed through the EHRA Research Network, National Societies, and social media between January and February 2023. One hundred and eighty-one physicians responded the survey, 61% from university hospitals. Atrial fibrillation screening in high-risk patients is regularly performed by 57%. Only 42% has access to at least one programme aiming at diagnosing/managing comorbidities and lifestyle modifications, with marked heterogeneity between countries. Direct oral anticoagulants are the preferred antithrombotic (97%). Rhythm control is the preferred strategy in most AF phenotypes: symptomatic vs. asymptomatic paroxysmal AF (97% vs. 77%), low vs. high risk for recurrence persistent AF (90% vs. 72%), and permanent AF (20%). I-C drugs and amiodarone are preferred while dronedarone and sotalol barely used. Ablation is the first-line therapy for symptomatic paroxysmal AF (69%) and persistent AF with markers of atrial disease (57%) and is performed independently of symptoms by 15%. In persistent AF, 68% performs only pulmonary vein isolation and 32% also additional lesions.
CONCLUSION: There is marked heterogeneity in AF management and limited accordance to last guidelines in the EHRA community. Most of the discrepancies are related to the main controversial issues, such as those related to AF screening, management of comorbidities, pharmacological treatment, and ablation strategy.
INTRODUCTION: The aim of the present study was to evaluate the prevalence and prognosis of structural heart disease (SHD) among competitive athletes with negative T waves without pathological findings at transthoracic echocardiogram.
METHODS: From a prospective register of 450 athletes consecutively evaluated during a second-level cardiological examination, we retrospectively identified all subjects with the following inclusion criteria: (1) not previously known cardiovascular disease; (2) negative T waves in leads other than V1-V2; (3) normal transthoracic echocardiogram. Patients underwent cardiac MRI and CT. The primary endpoint was the diagnosis of definite SHD after multimodality imaging evaluation. A follow-up was collected for a combined end-point of sudden death, resuscitated sudden cardiac death and hospitalization for any cardiovascular causes.
RESULTS: A total of 55 competitive athletes were finally enrolled (50 males, 90%) with a mean age of 27.5 ± 14.1 years. Among the population enrolled 16 (29.1%) athletes had a final diagnosis of SHD. At multivariate analysis, only deep negative T waves remained statistically significant [OR (95% CI) 7.81 (1.24-49.08), p = 0.0285]. Contemporary identification of deep negative T waves and complex arrhythmias in the same patients appeared to have an incremental diagnostic value. No events were collected at 49.3 ± 12.3 months of follow-up.
CONCLUSIONS: In a cohort of athletes with negative T waves at ECG, cardiac MRI (and selected use of cardiac CT) enabled the identification of 16 (29.1%) subjects with SHD despite normal transthoracic echocardiography. Deep negative T waves and complex ventricular arrhythmias were the only clinical characteristic associated with SHD diagnosis.
Spinal stabilization exercises for the lumbar region will be given in 3 phases following the protocol given to the chiropractic manipulation group. The exercises will be performed two days a week under the supervision of a physiotherapist. Individuals will be called to the hospital two days a week for 8 weeks and will be advised to continue the exercises during the follow-up period. At the end of the 12th week, the exercises will be repeated and progressed with the physiotherapist.
OBJECTIVE: This article reviews the clinical and antibody spectrum of autoimmune cerebellar ataxia and other autoimmune movement disorders. It highlights characteristic phenotypes and red flags to the diagnosis and how these rare, but treatable, disorders are integrated into a differential diagnosis.
LATEST DEVELOPMENTS: An increasing number of neuronal antibodies have been identified in patients with cerebellar ataxia, for example, against Kelch-like protein 11 (KLHL11), seizure-related 6 homolog-like 2, septin-3 and septin-5, or tripartite motif containing protein 9 (TRIM9), TRIM46, and TRIM67. Ig-like cell adhesion molecule 5 (IgLON5) antibody-associated syndromes have emerged as an important alternative diagnostic consideration to various neurodegenerative diseases such as Huntington disease or atypical parkinsonism. Opsoclonus-myoclonus syndrome emerged as the most relevant parainfectious movement disorder related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
ESSENTIAL POINTS: Autoimmune cerebellar ataxia and other autoimmune movement disorders encompass a broad spectrum of different clinical syndromes, antibodies, and immunopathophysiologic mechanisms. Clinical acumen is key to identifying the cases that should undergo testing for neuronal antibodies. Given the overlap between phenotypes and antibodies, panel testing in serum and CSF is recommended.
Snoring intensity would be measured using a calibrated microphone-sound meter system. The 2 microphones will be suspended at a distance of 1 m approximately above the surface of the patient's bed. This arrangement allows a non-invasive measurement of snoring that simulates the distance between sleeping bed partners. Before every study the system would be acoustically calibrated using a reference noise produced by a noise generator (86 dB). The signal would be sent at a sampling rate of 12 KHz through an analogue-digital converter to a computer system for subsequent analysis. All digitized signals will be recorded in the hard disk of a personal computer. A noise analyzer (Praat; Boersma 2005) will be used for the intensity analysis of snoring sound (Boersma, 2005).
Rett syndrome (RTT) is a rare but dreadful X-linked genetic disease that mainly affects young girls. It is a neurological disease that affects nerve cell development and function, resulting in severe motor and intellectual disabilities. To date, no cure is available for treating this disease. In 90% of the cases, RTT is caused by a mutation in methyl-CpG-binding protein 2 (MECP2), a transcription factor involved in the repression and activation of transcription. MECP2 is known to regulate several target genes and is involved in different physiological functions. Mouse models exhibit a broad range of phenotypes in recapitulating human RTT symptoms; however, understanding the disease mechanisms remains incomplete, and many potential RTT treatments developed in mouse models have not shown translational effectiveness in human trials. Recent data hint that the zebrafish model emulates similar disrupted neurological functions following mutation of the mecp2 gene. This suggests that zebrafish can be used to understand the onset and progression of RTT pathophysiology and develop a possible cure. In this review, we elaborate on the molecular basis of RTT pathophysiology in humans and model organisms, including rodents and zebrafish, focusing on the zebrafish model to understand the molecular pathophysiology and the development of therapeutic strategies for RTT. Finally, we propose a rational treatment strategy, including antisense oligonucleotides, small interfering RNA technology and induced pluripotent stem cell-derived cell therapy.
The purpose of the research was to explore the effects of aromatherapy on pain, sleep quality, and psychological distress in patients with rheumatoid arthritis. The subjects of the study adopted the intentional sampling method, and the place of collection was patients with rheumatoid arthritis in the outpatient department of the rheumatology and immunology department of the hospital. The study was conducted with a randomized controlled trial design. It is estimated that 159 patients with rheumatoid arthritis will be admitted, and the participants will be randomly allocated into the experimental group, the comfort group and the control group with 53 participants. The experimental group received base oil and essential oil massage, the comfort group only received base oil massage for 10 minutes each time, three times a week for three weeks, and the control group did not receive any intervention measures. Repeated measurements were used to collect data using structured questionnaires. Pain was measured by the Numerical Rating Scale, and sleep quality was measured by the Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale. Scale) measurement and psychological distress were measured by the Hospital Anxiety and Depression Scale. Data were collected at four time points before the intervention, the first week, the second week, and the third week after the intervention. The data obtained are processed and analyzed using SPSS version 22.00 computer software. Statistical analysis methods include independent sample single-factor variance analysis to compare the differences in basic data and pain levels between the experimental group, the comfort group and the control group; repeated measurement of single-factor variation Analyze the comparison of intra-group differences among the three groups at four time points; finally, compare the effects of the three groups on pain and sleep quality after aromatherapy interventions using the generalized estimation equation.
Bovine viral diarrhea virus (BVDV) belongs to the genus Pestivirus within the family Flaviviridae. Mitophagy plays important roles in virus-host interactions. Here, we provide evidence that non-cytopathic (NCP) BVDV shifts the balance of mitochondrial dynamics toward fission and induces mitophagy to inhibit innate immune responses. Mechanistically, NCP BVDV triggers the translocation of dynamin-related protein (Drp1) to mitochondria and stimulates its phosphorylation at Ser616, leading to mitochondrial fission. In parallel, NCP BVDV-induced complete mitophagy via Parkin-dependent pathway contributes to eliminating damaged mitochondria to inhibit MAVS- and mtDNA-cGAS-mediated innate immunity responses, mtROS-mediated inflammatory responses and apoptosis initiation. Importantly, we demonstrate that the LIR motif of ERNS is essential for mitophagy induction. In conclusion, this study is the first to show that NCP BVDV-induced mitophagy plays a central role in promoting cell survival and inhibiting innate immune responses in vitro.
<P>PROBLEM TO BE SOLVED: To provide a pressure-sensitive adhesive composition for an adhesive skin patch, capable of achieving excellent cohesion and skin adhesiveness at a high level.  <P>SOLUTION: The pressure-sensitive adhesive composition for the adhesive skin patch includes rubber elastomer and a tackifier whose weight average molecular weight is 1200-2500. Because of this characteristic, both excellent cohesion and skin adhesiveness can be achieved at a high level. In this way, by using the pressure-sensitive adhesive composition for the adhesive skin patch to form a pressure-sensitive adhesive layer of the adhesive skin patch or adhesive preparation, the adhesiveness to the skin is improved, and the paste left on the skin surface when the adhesive skin patch is removed is reduced. Further, leaving of the paste in a mold release film from the pressure-sensitive adhesive layer at the time of manufacture or at the time of use and the floating of the mold release film can be inhibited, and re-application of the adhesive skin patch to the skin is possible.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Because strategies for the management of overdose are continually evolving, it is advisable to contact a Certified Poison Control Center to determine the latest recommendations for the management of an overdose of any drug.

One overdose of 7200 mg per day rufinamide was reported in an adult during the clinical trials. The overdose was associated with no major signs or symptoms, no medical intervention was required, and the patient continued in the study at the target dose.

Treatment or Management of Overdose: There is no specific antidote for overdose with rufinamide. If clinically indicated, elimination of unabsorbed drug should be attempted by induction of emesis or gastric lavage. Usual precautions should be observed to maintain the airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient.

Hemodialysis: Standard hemodialysis procedures may result in limited clearance of rufinamide. Although there is no experience to date in treating overdose with hemodialysis, the procedure may be considered when indicated by the patient’s clinical state.
Extracts of green tea useful as antithrombotic agent based on catechins in its leaves is provided. Dried leaves of green tea are extracted in hot water or mixture of water and lower alcohols. Extracting solution is filtered to remove insoluble substances. Filtrates obtained is concentrated at 50-70 deg.C for 30 mins-2 hrs under the reduced pressure. Concentrates is extracted repeatedly in ethylacetate to obtain the organic solvent layor and then separated it by column chromatography using mixture of water and acetone, dioxane, methanol or isopropanol as separating solvent. Solution separated is freeze-dried to give green tea extracts powder whose component is polyphenols 25-30%, epigallocatechin gallate 40-70%, mixture of epicatechin and epigallocatechin 0-35%.
Painful Diabetic Neuropathy (PDN) is a common diabetes complication that frequently causes severe hyperalgesia and allodynia and presents treatment challenges. Mitochondrial-derived peptide (MOTS-c), a novel mitochondrial-derived peptide, has been shown to regulate glucose metabolism, insulin sensitivity, and inflammatory responses. This study aimed to evaluate the effects of MOTS-c in streptozocin (STZ)-induced PDN model and investigate the putative underlying mechanisms. We found that endogenous MOTS-c levels in plasma and spinal dorsal horn were significantly lower in STZ-treated mice than in control animals. Accordingly, MOTS-c treatment significantly improves STZ-induced weight loss, elevation of blood glucose, mechanical allodynia, and thermal hyperalgesia; however, these effects were blocked by dorsomorphin, an adenosine monophosphate-activated protein kinase (AMPK) inhibitor. In addition, MOTS-c treatment significantly enhanced AMPKα1/2 phosphorylation and PGC-1α expression in the lumbar spinal cord of PDN mice. Mechanistic studies indicated that MOTS-c significantly restored mitochondrial biogenesis, inhibited microglia activation, and decreased the production of pro-inflammatory factors, which contributed to the alleviation of pain. Moreover, MOTS-c decreased STZ-induced pain hypersensitivity in PDN mice by activating AMPK/PGC-1α signaling pathway. This provides the pharmacological and biological evidence for developing mitochondrial peptide-based therapeutic agents for PDN.
FIELD: medicine. SUBSTANCE: invention refers to vaccine used for protecting against infecting by Yersinia pestis microorganism and to the method for protecting human or animal body against Y.pestis infection due to injecting such a vaccine. The vaccine contains immunogenously efficient quantity of V- and FI-antigen or epitopic part of each of them, or microorganisms expressing V- and F1-antigens either separately or together and referring to Yersinia pestis-different species. The present vaccine is capable to induce protective immune response without any side effects. EFFECT: higher efficiency. 31 cl, 2 dwg, 6 ex, 3 tbl
Infants randomized to the study arm will receive oral morphine 0.05 mg/kg/dose as needed for an elevated Finnegan score. May receive morphine as frequently as every 3 hours if needed.
Cohort 2 will be comprised 30 participants with recurrent IDH mutant glioma before receiving surgical resection. Participants will be injected with 0.67ml/kg actual body weight of 100 millimolar (mM) of α-KG solution and have a single imaging scan.
Vitamin D, Albumin, CRP, TAS and TOS values will be checked before and during the operation in 36 patients who will receive general anesthesia. Flow of 4 L/min will be given during the operation. The processed EEG values of all patients will be monitored and they will be ensured to be at the same anesthesia depth. Albumin, CRP, TAS and TOS values will be checked again from the blood taken postoperatively in the patients who were taken to the service after the operation and these values will be compared with the previous ones.
This study is a double-blinded prospective randomized control trial. Patients will be randomized in a 1:1 ratio to either the liposomal bupivacaine group versus bupivacaine alone. Randomization assignment will be determined using a computer program based on random number generation, with an equal number of treatments in blocks of 2, 4, and 6 patients. The order of the blocks will be randomized as well. Treatment assignments will be concealed in sequentially numbered opaque sealed envelopes (SNOSE). The anesthesia provider administering the medication will not be an investigator of this study and will be allowed to know what medication that is administered to ensure safety with regards to any potential medication interactions the study medication may have with any other medication or anesthesia provided during the operation. This study will be double blinded by having the associate investigator (anesthesia resident/fellow) that will be conducting the post-operative pain score, Defense and Veterans Pain Rating Scale (DVPRS) evaluations, un-aware of which medication each patient received during the fascial iliac regional soft tissue infiltration blockade. The anesthesia resident/fellow will remain blinded to which medication the patient received by not having access to the patients electronic medical record, did not participate in the procedure, and will not have access to the database created by the orthopaedics residents where this information will be entered. The treating surgeons will also be blinded to which medication was administered by not being present during the randomization process and will only be made aware of which medication the patient received after the final two-week postoperative pain assessment and oral pain medication pill count, after which patient study participation will be concluded. The success of blinding will be evaluated by asking the patient, anesthesia resident/fellow and treating surgeon to guess their treatment assignment the day of surgery, during the pain score collection process and at the final two-week routine follow up appointment.
The invention discloses a method for establishing a high-performance liquid chromatography (HPLC) fingerprint of Guangxi dendrobium candidum wall. ex lindl, which comprises the following steps of: moisturizing dendrobium candidum wall. ex lindl powder with 10 percent ammonia water; performing reflux extraction for 4 h in a methanol water-bath at the temperature of 85 DEG C; filtering the extract and drying the filtered product by distillation; fixing a constant volume with methanol; passing solution through a microporous filter membrane; and performing chromatographic assay on filtrate to obtain the HPLC fingerprint of the dendrobium candidum wall. ex lindl, wherein the HPLC assay conditions are that: a chromatographic column is Alltima C18 (with an area of 4.6mm*250mm wide and a length of 5 mu m long), acetonitrile-0.1 percent water solution of phosphoric acid serving as a flow phase is used for gradient eluting at a flow speed of 1.2mL/min, a detection wavelength is 300nm, and a column temperature is 30 DEG C. The invention also discloses a standard fingerprint prepared by the method, and the standard fingerprint has 13 common chromatographic peaks. The method in the invention is precise, stable and high in repeatability, and the obtained fingerprint can provide scientific reference for manual rational collection and the quality control of the dendrobium candidum wall. ex lindl.
Genotyping for CYP2C9\*2, CYP2C9\*3, and VKORC1 (-1639G→A) was performed with the use of a point-of-care test. For patients assigned to the genotype-guided group, warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days.
Subjects with moderate renal impairment. eGFR (by MDRD equation) range 30 - 59 mL/min/1.73 m2 as determined at Screening.
Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients whose disease is not responding after the first course may crossover to group 2.
Material for tooth reconstructions is produced by subjecting to polymerizing conditions a composition essentially comprising a mixture of polymeric methyl methacrylate and monomeric methyl methacrylate containing a minor proportion of methallylmethacrylate. Alternatively, a composition essentially comprising a mixture of an interpolymer formed by polymerizing methylmethacrylate with a minor proportion of methallylmethacrylate, and monomeric methylmethacrylate containing a minor proportion of methallylmethacrylate, or a composition essentially comprising a mixture of an interpolymer formed by polymerizing methylmethacrylate with a minor proportion of methallylmethacrylate, and monomeric methylmethacrylate, may be polymerized.  The weight of methallylmethacrylate in the final product is preferably between 0.9 and 5 per cent.  Polymerization inhibitors, e.g. hydroquinone, thermo-polymerization catalysts, e.g. benzoyl peroxide, or photo - polymerization catalysts, e.g. benzoin, may be incorporated, as may also suitable pigments or dyes.  Specific characteristics may be imparted to the product by replacing minor proportions of the methylmethacrylate by other acrylic and methacrylic esters, as well as interpolymers with one another or with other polymerizable substances.  Specification 569,974 is referred to.
An access port for transporting fluids into a patient's body utilizing a multiple seals in parallel is disclosed. The access port 100 includes a flanged base 102, a receptacle 106 with multiple seals 108 and 110, and a cannula 104. The access port may also include a guide needle for installation purposes, and a sanitary adaptor that seals the receptacle for long term usage. Adhesives or bandaging may utilize the flanged base to secure the access port to the patient. The flanged base may also be installed beneath the patient's skin so secure the access port. The receptacle utilizes a multitude of sealing mechanism, including but not limited to O-ring seals and screw-lock seals. The receptacle additionally contains and outlet flow path leading to the cannula. The cannula connects from the receptacle into the patient's body. The cannula is installed perpendicular to the plane of the flanged base and protrudes on the side of the access port facing into the patient's body while the receptacle faces outward. A number of devices may work in conjunction to access port 100 that interface with the multiple parallel seal mechanism. Guide needle 200 may be utilized during installation, sanitary seal 300 may be used for long term use, and band 500 in conjunction with bag 600 may be worn on a patient to deliver substances into their body. Programmable components 512, 606, and 712 may be implemented with these devices that enables a system that automatically identifies the substance being administered and dosing information, then relays that information to a doctor or caregiver.